ReviewBMC veterinary research2026
Actinobacillus pleuropneumoniae - today's perspective on advances and challenges (2017- 2026).
Review in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinobacillus pleuropneumoniae (APP) remains one of the most significant bacterial respiratory pathogens in swine production worldwide, causing porcine pleuropneumonia with substantial economic impact. Although recent reviews have summarized aspects of APP epidemiology, serotyping, surface-associated virulence determinants, and vaccine development strategies, several complementary research areas have advanced rapidly since the last DISease CONtrol TOOLS (DISCONTOOLS) 2017 report on this bacterium. These include antimicrobial resistance surveillance, chronic persistence mechanisms such as biofilm formation, refined experimental infection models, intracellular survival within host immune cells, and the immunopathological processes driving lung injury. This review focuses on these practical and mechanistic dimensions, emphasizing their relevance for herd-level control, outbreak management, and future therapeutic approaches. Recent genomic studies of multidrug-resistant strains, as well as the development of improved molecular diagnostic tools, are also discussed. Collectively, emerging evidence suggests that APP should not be viewed solely as an extracellular pathogen causing acute disease outbreaks, but rather as an adaptable organism capable of persistence, immune modulation, and endemic circulation in modern pig populations. Addressing these challenges will require integrated strategies that combine antimicrobial stewardship, improved surveillance, and a deeper understanding of host-pathogen interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.